Pulmonx strives to be the cornerstone of interventional pulmonology by focusing on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide.
Pulmonx is a privately-held commercial stage medical device company focused on developing both diagnostic and therapeutic technologies for Interventional Pulmonology. The Company’s first commercial products address emphysema, a form of COPD and the largest unmet medical need in Pulmonology. Pulmonx has developed the Endobronchial Valve (EBV) Therapy, a non-surgical approach to treating emphysema that uses the Chartis Pulmonary Assessment System to optimize the placement of a series of unique self-expanding valves. The Zephyr® Endobronchial Valve is designed to reduce the volume of the diseased region of the lung by blocking airflow. In the United States, Pulmonx is conducting the LIBERATE Clinical Study to evaluate the safety and effectiveness of the Zephyr valve in patients with severe emphysema.
Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. The company does not yet market or sell its products in the United States.